TY - JOUR
T1 - Wavefront-guided laser in situ keratomileusis with the Alcon CustomCornea and the VISX CustomVue
T2 - Three-month results
AU - Awwad, Shady T.
AU - El-Kateb, Mohamed
AU - Bowman, Robert W
AU - Cavanagh, Harrison D
AU - McCulley, James P
PY - 2004/9/1
Y1 - 2004/9/1
N2 - PURPOSE: To evaluate and compare the visual and clinical outcomes of wavefront-guided laser in situ keratomileusis (LASIK) with the Alcon CustomCornea (Alcon Laboratories Inc, Fort Worth, Tex) and VISX CustomVue (VISX, Santa Clara, Calif) systems. METHODS: Ninety-three eyes of 56 patients (50 and 43 consecutive eyes on CustomCornea and CustomVue, respectively) were enrolled in a prospective multisurgeon clinical outcome study. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and manifest refraction were measured at 1 day, 1 week, 1 month, and 3 months postoperatively. Early treatment diabetic retinopathy study (ETDRS) visual acuity and contrast sensitivity were measured at 1 month and 3 months, and wavefront mapping at 3 months. RESULTS: Preoperatively, the CustomCornea group had a mean sphere of -3.90 ± 1.62 diopters (D) (range -0.50 to -7.25 D), mean cylinder of +0.62 ± 0.39 D (range 0 to +1.50 D), and mean manifest spherical equivalent refraction of -3.59 ± 1.54 D. The CustomVue group had a sphere of -3.87 ± 1.45 D (range -1.75 to -6.75 D), cylinder of +0.49 ± 0.36 D (range 0 to +1.50 D), and manifest spherical equivalent refraction of -3.62 ± 1.46 D. At 3 months, 98% of the CustomCornea group and 95% of the CustomVue group were within ±0.50 D. Ninety-nine percent of eyes did not change >0.50 D (manifest spherical equivalent refraction) between 1 month and 3 months. CustomCornea eyes improved on contrast sensitivity testing and had a better profile than CustomVue for 20/15 Snellen and 20/12.5 ETDRS acuity. Both laser groups had a decrease in higher order aberrations with statistical significance for coma and spherical aberration in the CustomCornea group. CONCLUSION: Wavefront-guided LASIK with both systems is safe and effective.
AB - PURPOSE: To evaluate and compare the visual and clinical outcomes of wavefront-guided laser in situ keratomileusis (LASIK) with the Alcon CustomCornea (Alcon Laboratories Inc, Fort Worth, Tex) and VISX CustomVue (VISX, Santa Clara, Calif) systems. METHODS: Ninety-three eyes of 56 patients (50 and 43 consecutive eyes on CustomCornea and CustomVue, respectively) were enrolled in a prospective multisurgeon clinical outcome study. Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and manifest refraction were measured at 1 day, 1 week, 1 month, and 3 months postoperatively. Early treatment diabetic retinopathy study (ETDRS) visual acuity and contrast sensitivity were measured at 1 month and 3 months, and wavefront mapping at 3 months. RESULTS: Preoperatively, the CustomCornea group had a mean sphere of -3.90 ± 1.62 diopters (D) (range -0.50 to -7.25 D), mean cylinder of +0.62 ± 0.39 D (range 0 to +1.50 D), and mean manifest spherical equivalent refraction of -3.59 ± 1.54 D. The CustomVue group had a sphere of -3.87 ± 1.45 D (range -1.75 to -6.75 D), cylinder of +0.49 ± 0.36 D (range 0 to +1.50 D), and manifest spherical equivalent refraction of -3.62 ± 1.46 D. At 3 months, 98% of the CustomCornea group and 95% of the CustomVue group were within ±0.50 D. Ninety-nine percent of eyes did not change >0.50 D (manifest spherical equivalent refraction) between 1 month and 3 months. CustomCornea eyes improved on contrast sensitivity testing and had a better profile than CustomVue for 20/15 Snellen and 20/12.5 ETDRS acuity. Both laser groups had a decrease in higher order aberrations with statistical significance for coma and spherical aberration in the CustomCornea group. CONCLUSION: Wavefront-guided LASIK with both systems is safe and effective.
UR - http://www.scopus.com/inward/record.url?scp=4644317870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4644317870&partnerID=8YFLogxK
M3 - Review article
C2 - 15523984
AN - SCOPUS:4644317870
SN - 1081-597X
VL - 20
SP - S606-S613
JO - Journal of Refractive Surgery
JF - Journal of Refractive Surgery
IS - 5
ER -